Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This research focuses on classifying genetic variants found in families with a history of hereditary cancer, especially breast and ovarian cancers. It aims to improve genetic counseling by studying the co-segregation of specific gene variants, including those in BRCA1, BRCA2, PALB2, and other genes tested in multigene panels. The study uses data from large French national databases to better understand the disease risk linked to these variants and to support clinical decision-making. Participants include index cases carrying variants of interest classified as class 3 variants of uncertain significance, class 4 likely pathogenic, or hypomorphic class 5 with intermediate effects. The study collects saliva samples from family members to test for these variants and applies statistical models to evaluate the likelihood that a variant causes disease. Genetic analyses are performed by partner laboratories, and results contribute to refining variant classification and recommendations. During the study, participants provide saliva samples for genetic testing and consent to share their data anonymously for analysis. Researchers monitor co-segregation of variants with disease in families over up to 15 years. The main outcome is the classification of selected variants based on family data, which may impact genetic counseling and clinical management. Results are shared at the group level without revealing individual test outcomes.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the impact of liquid biopsy technology to improve treatment for patients with metastatic cancer receiving care in community hospitals. This prospective biomarker study aims to demonstrate how analyzing circulating tumor DNA ctDNA using a large gene panel and microsatellite instability testing can help guide personalized therapy decisions. The study includes patients with various metastatic solid tumors, including castration-resistant prostate cancer and certain types of metastatic breast cancer resistant to standard therapies. Participants will have a blood sample taken at the start of their first-line treatment, which may include chemotherapy, immunotherapy, endocrine therapy, or targeted therapy. The collected plasma samples will undergo Next Generation Sequencing NGS to detect gene alterations and MSI status. Results will be reviewed by a Molecular Tumor Board MTB that includes specialists from multiple centers to discuss treatment options based on the molecular profile. During the study, researchers will monitor the proportion of patients with successful ctDNA sequencing and how often molecular profiling information guides treatment. They will also evaluate response rates, survival outcomes, and the timing between liquid biopsy and therapy initiation over a follow-up period of 72 months. Patients will be assessed for measurable disease, performance status, and compliance with study procedures, including providing informed consent. The study carefully tracks safety and effectiveness of molecular-guided therapy in a community oncology setting.